Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Clinical Trial of CPI-613 in Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-grade B-cell Lymphoma With Rearrangements of MYC and BCL2 and/or BCL6

Trial Profile

A Phase II Clinical Trial of CPI-613 in Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-grade B-cell Lymphoma With Rearrangements of MYC and BCL2 and/or BCL6

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Jan 2019

At a glance

  • Drugs CPI 613 (Primary)
  • Indications B-cell lymphoma; Burkitt's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Jan 2019 According to a Rafael Pharmaceuticals media release, the company has intiated the patient enrollment in this study.
    • 04 Jul 2018 New trial record
    • 29 Jun 2018 According to a Rafael Pharmaceuticals media release, Dr. Noy from Memorial Sloan-Kettering Cancer Center is the principal investigator for this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top